Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) and Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
Volatility & Risk
Werewolf Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.77, suggesting that its stock price is 177% more volatile than the S&P 500.
Earnings & Valuation
This table compares Werewolf Therapeutics and Tenaya Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Werewolf Therapeutics | $1.88 million | 25.00 | -$60.82 million | ($0.76) | -1.27 |
| Tenaya Therapeutics | $1.33 million | 118.92 | -$90.60 million | ($0.53) | -1.34 |
Werewolf Therapeutics has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Werewolf Therapeutics and Tenaya Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Werewolf Therapeutics | N/A | -166.99% | -59.88% |
| Tenaya Therapeutics | N/A | -83.75% | -66.53% |
Analyst Ratings
This is a breakdown of current ratings for Werewolf Therapeutics and Tenaya Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Werewolf Therapeutics | 1 | 4 | 2 | 0 | 2.14 |
| Tenaya Therapeutics | 1 | 0 | 5 | 1 | 2.86 |
Werewolf Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 313.65%. Tenaya Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 464.97%. Given Tenaya Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than Werewolf Therapeutics.
Summary
Tenaya Therapeutics beats Werewolf Therapeutics on 9 of the 14 factors compared between the two stocks.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
About Tenaya Therapeutics
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
